A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

• Status: Completed
• Trial end date: 2017-10-11
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Faes Farma, S.A.
• Collaborator: ORA, Inc.
• Treatments: Ophthalmic Solutions

Criteria

Key Inclusion Criteria:

• be at least 18 years old

• be willing and able to avoid all disallowed medications and contact lenses

• must have a pregnancy test if of childbearing potential

• must be able to read an eye chart from 10 feet away

Key Exclusion Criteria:

• must not have any allergies to the study medications

• must not have any ocular or non ocular condition that investigator feels will interfere with study parameters

• must not have used immunotherapy in the last 2 years

• must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial